Switching to bictegravir/ emtricitabine/tenofovir alafenamide plus darunavir/cobicistat in heavily antiretroviralexperienced, virologically suppressed HIV-infected adults receiving complex regimens: 48-week analysis

被引：0

作者：

Podzamczer, D. ^{[1
]}

Imaz, A. ^{[2
]}

Lopez-Lirola, A. ^{[3
]}

Knobel, H. ^{[4
]}

Masia, M. ^{[5
]}

Fanciulli, C. ^{[6
]}

Hernadez, C. ^{[7
]}

Lagarde, M. ^{[8
]}

Gutierrez, A. ^{[9
]}

Curran, A. ^{[10
]}

Morano, L. ^{[11
]}

Montero-Alonso, M. ^{[12
]}

Troya, J. ^{[13
]}

Rigo, R.

Casadella, M. ^{[14
]}

Navarro-Alcaraz, A. ^{[14
]}

Ardila, F.

Parera, M. ^{[14
]}

Bernal, E. ^{[15
]}

Echeverria, P. ^{[16
]}

Estrada, V. ^{[17
]}

Hidalgo-Tenorio, C. ^{[18
]}

Macias, J. ^{[19
]}

Priet, P. ^{[20
]}

Portilla, J. ^{[21
]}

Valencia, E. ^{[22
]}

Vivancos, M. J. ^{[23
]}

Rivero, A.

机构：

[1] Fight Infect Fdn, Badalona, Spain

[2] Hosp Univ Bellvitge, Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain

[3] Hosp Univ Canarias, San Cristobal la Laguna, Spain

[4] Hosp Univ Gen Elche, Elche, Spain

[5] Hosp Gen Univ Gregorio Maran, Inst Invest Sanitaria Gregorio Maran IiSGM, Ctr Invest Biomed Red Enfermedades Infecc, Madrid, Spain

[6] Hosp Principe Asturias, Alcala De Henares, Spain

[7] Hosp Univ 12 Octubre, Madrid, Spain

[8] Hosp Univ Princesa, Madrid, Spain

[9] Hosp Univ Vall dHebron, Barcelona, Spain

[10] Hosp Univ Alvaro Cunqueiro, Vigo, Spain

[11] Hosp Univ Politecn La Fe, Valencia, Spain

[12] Hosp Univ Infanta Leonor, Madrid, Spain

[13] IrsiCaixa Inst Recerca SIDA, Badalona, Spain

[14] Hosp Univ Reina Sofia, Murcia, Spain

[15] Hosp Badalona Germans Trias & Pujol, Fight Infect Fdn, Badalona, Spain

[16] Hosp Clin San Carlos, Madrid, Spain

[17] Hosp Univ Virgen de Ias Nieves, Granada, Spain

[18] Univ Seville, IBiS,Hosp Univ Virgen de Valme, Inst Biomed Sevilla,Unidad Enfermedades Infecc &, CIBERINFEC,Dept Med,CSIC, Seville, Spain

[19] Hosp Univ Santa Creu & St Pau, Barcelona, Spain

[20] Hosp Gen Univ Alicante, Alicante, Spain

[21] Hosp Univ La Paz, Madrid, Spain

[22] Hosp Univ Ramon y Cajal, Madrid, Spain

[23] Univ Cordoba UCO, Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed Cordoba IMIBIC, ISCIII CIBER Enfermedades Infecc Inst Salud Carlo, Cordoba, Spain

来源：

HIV MEDICINE | 2023年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

EACS2023:

引用

下载

页码：310 / 311

页数：2

共 50 条

[41] Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial
Kityo, Cissy
Hagins, Debbie
Koenig, Ellen
Avihingsanon, Anchalee
Chetchotisakd, Ploenchan
Supparatpinyo, Khuanchai
Gankina, Natalya
Pokrovsky, Vadim
Voronin, Evgeny
Stephens, Jeffrey L.
DeJesus, Edwin
Wang, Hui
Acosta, Rima K.
Cao, Huyen
Quirk, Erin
Martin, Hal
Makadzange, Tariro
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 82 (03) : 321 - 328
[42] Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial (vol 5, pg e545, 2018)
Molina, J-M
Ward, D.
Brar, I
LANCET HIV, 2018, 5 (10): : E545 - E545
[43] Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial
Winston, Alan
Post, Frank A.
DeJesus, Edwin
Podzamczer, Daniel
Di Perri, Giovanni
Estrada, Vicente
Raffi, Francois
Ruane, Peter
Peyrani, Paula
Crofoot, Gordon
Mallon, Patrick W. G.
Castelli, Francesco
Yan, Mingjin
Cox, Stephanie
Das, Moupali
Cheng, Andrew
Rhee, Martin S.
LANCET HIV, 2018, 5 (04): : E162 - E171
[44] SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen (vol 56, pg 1637, 2013)
Campo, R.
DeJesus, E.
Bredeek, U. F.
Henry, K.
Khanlou, H.
Logue, K.
CLINICAL INFECTIOUS DISEASES, 2013, 57 (05)
[45] Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study
Blanco, Jose L.
Rojas, Jhon
de Lazzari, Elisa
Inciarte, Alexy
Subirana, Mar
Callau, Pilar
Martinez-Rebollar, Maria
Laguno, Montserrat
Mallolas, Josep
de la Mora, Lorena
Torres, Berta
Gonzalez-Cordon, Ana
Martinez, Esteban
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (07) : 1974 - 1979
[46] Phase IIIb, randomized, open-label study to evaluate switching from a tenofovir disoproxil fumarate (TDF)-containing regimen to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed, HIV-1 infected participants aged ≥60
Maggiolo, F.
Rizzardini, G.
Raffi, F.
Pulido, F.
Mateo Garcia, G.
Molina, J.
Ong, E.
Shao, Y.
Corales, R.
McNicholl, I.
Piontkowsky, D.
Das, M.
Haubrich, R.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
[47] Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
Arribas, Jose R.
Pialoux, Gilles
Gathe, Joseph
Di Perri, Giovanni
Reynes, Jacques
Tebas, Pablo
Thai Nguyen
Ebrahimi, Ramin
White, Kirsten
Piontkowsky, David
LANCET INFECTIOUS DISEASES, 2014, 14 (07): : 581 - 589
[48] Effect of age on efficacy and safety of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed, HIV-1-infected participants aged ≥ 65 years: pooled analysis of two Phase III trials
Maggiolo, F.
Rizzardini, G.
Raffi, F.
Pulido, F.
Mateo Garcia, G.
Molina, J.
Ong, E.
Shao, Y.
Chuck, S.
McNicholl, I.
Piontkowsky, D.
Das, M.
Haubrich, R.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
[49] Switch to fi xed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial
Zhang, Fujie
Wu, Hao
Cai, Weiping
Ma, Ping
Zhao, Qingxia
Wei, Hongxia
Lu, Hongzhou
Wang, Hui
He, Shenghua
Chen, Zhu
Chen, Yaokai
Wang, Min
Wan, Wan
Fu, Heliang
Qin, Hong
LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 49
[50] Efficacy and safety of the once-daily, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (STR) in ART-naive, HIV-1-infected adults: AMBER Week 96 results
Orkin, C.
Eron, J.
Rockstroh, J.
Podzamczer, D.
Esser, S.
Vandekerckhove, L.
Van Landuyt, E.
Lathouwers, E.
Hufkens, V.
Jezorwski, J.
Opsomer, M.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21

← 1 2 3 4 5 →